MDS Pharma Services Expands Drug Discovery Capability in Asia

    Investment Supports and Reflects Contract Research Organization's
    Recently Announced Strategic Focus on Discovery Through Phase IIa

    KING OF PRUSSIA, PA, June 8 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions, today
announced that a renovation and expansion of its discovery pharmacology
operation in Taiwan is under way to serve the growing global demand for work
performed in Asia.
    The renovation and expansion, which will be completed in 2010, is aligned
with the new MDS Pharma Services strategic focus on Early Stage operations -
Discovery through Phase IIa proof-of-concept services, and its commitment to
serve clients in an important emerging market.
    The Taiwan facility supports both molecular screening and profiling, as
well as in vivo safety and efficacy testing, and the renovation plan calls for
significant expansions and upgrades in each area. In vivo capacity has been
doubled, and will include dedicated space tailored to individual client needs.
Furthermore, the site's automated molecular screening and profiling capability
and efficiency will be improved with additional robotic high-throughput
screening capacity and analytical support.
    "This new and expanded facility will cement our position as the global
leader in the discovery pharmacology space, where we are one of the top two
providers of molecular screening, and a key supplier of in vivo efficacy and
safety testing," said MDS Pharma Services President David Spaight. "This
investment builds on a 40-year track record of success in this service area,
and supports our recently announced strategic focus on the Discovery through
Phase IIa Proof-of-Concept segment of the outsourcing market."
    The Taiwan site is part of MDS Pharma Services' Pharmacology/DMPK line of
service, which offers molecular, cellular, ADME/DMPK and in vivo assays for
use in identifying lead drug candidates, profiling for selectivity,
determining potential for adverse events, evaluating efficacy and establishing
proof of concept. To help speed lead optimization earlier in the discovery
phase and streamline the surest path to the clinic, the Taiwan facility offers
extensive capabilities in molecular and cellular pharmacology, including more
than 800 assays, multiple assay methodologies, high-throughput screening with
robotic automation, and expert assay development.
    To view the extensive catalog of discovery assays, visit the MDS Pharma
Services' Pharmacology/DMPK Website at

    More Information

    Additional background materials pertaining to MDS Pharma Services new
strategic focus on Early Stage Operations (Discovery through Phase IIa) can be
found on MDS Inc.'s Website at

    About MDS Pharma Services

    MDS Pharma Services, a business unit of MDS Inc., is committed to
delivering quality service on-time. We offer a full spectrum of resources to
meet the drug-discovery and development needs of the pharmaceutical and
biotechnology industries. With numerous facilities strategically located
around the world, we apply advanced scientific and technological expertise
throughout the drug discovery and development process - from lead
optimization, pre-IND research, early clinical research (bioequivalence,
Phases I-IIa) and bioanalysis through to global clinical development (Phases
IIb-IV), central lab and centralized cardiac services. For more information,
visit our website at

    About MDS Inc.

    MDS Inc. (TSX: MDS; NYSE:   MDZ), a global life-sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS has more
than 5,000 highly skilled people in 29 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

For further information:

For further information: MEDIA: Charlene McGrady, (610) 239-7900, ext.
231,; INVESTORS: Kim Lee, (905) 267-4230,

Organization Profile

Nordion Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890